5 Stocks to Watch: Week of 5/25/2026

Don't forget: The market is closed on Monday for Memorial Day! That said, there's plenty to be psyched about during the short trading week ahead, starting with these high-potential picks:

• Electromed Inc (ELMD) — Record Q3 results fuel double-digit growth momentum.
• Aveanna Healthcare Holdings (AVAH) — Home healthcare leader eyes 42% upside potential.
• Diebold Nixdorf Inc (DBD) — Strong Buy rating with 45% upside on the table. 
• Nature's Sunshine Products (NATR) — Wellness leader eyes 50% upside with #1 industry rank.
• Insulet Corporation (PODD) — Diabetes tech giant targets up to 187% upside surge.

Let's get to it.

A note from our sponsors...

1- Electromed (NYSEMKT: ELMD)

This innovative medical device maker — armed with its SmartVest airway clearance therapy system — is taking on the underserved bronchiectasis market with serious firepower. Record Q3 2026 results just delivered 18.4% revenue growth and strong operating leverage, positioning ELMD for sustained double-digit growth that has Wall Street paying close attention.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $38.58 — get current quote

Max 1-year forecast: $40.00

Why we're watching:

• Analyst support: While coverage is limited to 2 analysts, it is resoundingly bullish — both are Strong Buy ratings. See the ratings here
• B. Riley Securities researcher Kyle Bauser (a top 18% rated analyst) recently raised the price target to $40 following record Q3 2026 earnings. Bauser noted the quarter's "record" results were highlighted by 18.4% revenue growth and strong operating leverage, delivered by strength in homecare and a hospital rebound, and the company appears positioned for sustained double-digit growth supported by expanding adoption, payer coverage, and a large underpenetrated bronchiectasis market.
• The company delivered a 34.62% EPS beat in Q3 with actual earnings of $0.35 versus estimates of $0.26, while revenue grew 19.20% year-over-year to $18.58 million and beat expectations by 4.35%.
• Management highlighted that 86% of covered lives in the United States are now under contract and manufacturing optimization is complete, positioning the company to capture opportunities in the underserved bronchiectasis market.
• Industry ranking context: ELMD is currently the 2nd highest-rated stock in the Medical Device industry.
• Zen Rating highlights: ELMD is an A-rated stock in our Zen Ratings system, a tier that only includes the top 5% of the 4600+ stocks we track. All of these stocks have passed a rigorous 115-factor review with flying colors.
• Component Grades: The 115 factors we explore are divided into 7 Components, which are graded separately. The company excels with an A grade in Sentiment reflecting strong analyst optimism and an A grade in Financials backed by a healthy 14.1% profit margin and minimal debt-to-equity ratio of 0.21. See all 7 Zen Component Grades here

2- Insulet Corporation (NASDAQ: PODD)

The diabetes care leader behind the revolutionary Omnipod System — a self-adhesive, tubeless insulin delivery device that's reshaping diabetes management — is firing on all cylinders. PODD just earned a Strong Buy consensus from 17 analysts following recent earnings, with top-rated analysts setting price targets as high as $450 — a setup that's hard for growth investors to ignore.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $156.89 — get current quote

Max 1-year forecast: $450.00

Why we're watching:

• Strong upside potential: Looking for a stock that could nearly 2x? Right now, 13 of the analysts we track issue either Buy or Strong Buy ratings for PODD, with a max price target that suggests over 180% potential upside in the coming year. See the ratings
• Worth noting: Those targets aren’t stale. Multiple analysts raised or maintained Strong Buy ratings in early May 2026, with Canaccord Genuity’s Kyle Rose (a top 16% rated analyst) setting the highest price target at $450, which as noted above suggests significant upside potential.
• The company's financial forecasts show strong momentum with earnings expected to grow 33.54% and revenue growth of 17.84%, both significantly outpacing industry averages.
• Industry ranking context: PODD is currently the #4 highest-rated stock in the Medical Device industry, which has an Industry Rating of C.
• Zen Rating highlights: PODD earns an overall Zen Rating of A (Strong Buy) following a 115-factor fundamental review. It’s not easy to earn this rating — only the top 5% of stocks we track make the cut. 
• Component Grades: Each Zen Rating is composed of 7 Component Grades. The company's Financials component ranks exceptionally high, reflecting a strong balance sheet with 12% profit margins and robust operating cash flow of $619.3M. (See all 7 Zen Component Grades here)

3- Diebold Nixdorf (NYSE: DBD)

Diebold Nixdorf offers technology solutions to automate, manage, and secure cash and payments. The company is positioned as the 4th highest-rated stock in the App industry, benefiting from strong fundamentals and recent strategic appointments including a new Chief Information Officer.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $72.40 — get current quote

Max 1-year forecast: $100.00

Why we're watching:

• Analyst support: DBD receives coverage from 2 analysts with a consensus rating of Strong Buy, including 1 Strong Buy rating and 1 Buy rating. See the ratings
• DA Davidson researcher Matt Summerville (a top 11% rated analyst) recently maintained his Strong Buy rating with a $100 price target (suggesting over 38% potential upside) following strong confidence in the company's ability to generate sustainable growth and robust returns over the upcoming years.
• Analysts have expressed optimism about the company's strategic vision aligned with industry growth patterns, with the stock projected to outperform in the coming months supported by a solid management team.
• Industry ranking context: DBD is currently the 4th highest-rated stock in the App industry, which has an Industry Rating of B.
• Zen Rating highlights: A (Strong Buy) stocks average +32.52%/yr — DBD is in an elite tier of the stocks we track after having undergone a rigorous 115-factor review. 
• Component Grades: Looking at the Component Grades that shape the overall Zen Rating, DBD enjoys a strong Value grade (A) combined with solid Growth (B) and Safety (B). That suggests the stock may still be undervalued relative to its earnings potential, while also delivering improving business performance and maintaining a relatively stable financial and operational profile.(See all 7 Zen Component Grades here)

A note from our sponsors...

4- Aveanna Healthcare Holdings (NASDAQ: AVAH)

This nationwide home healthcare powerhouse — covering private duty nursing, adult home health and hospice, pediatric therapy, and enteral nutrition services — is firing on all cylinders. AVAH just topped Q1 2026 earnings and revenue estimates, announced revised 2026 guidance, and scored a fresh Strong Buy upgrade from Stephens & Co. that's putting it squarely on Wall Street's radar. 

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $7.67 — get current quote

Max 1-year forecast: $11.00

Why we're watching:

• Analyst support: AVAH enjoys 2 Strong Buy, 1 Buy, and 3 Hold ratings among the analysts we track — an overall Buy consensus. See the ratings
• Stephens & Co. researcher Scott Fidel (a top 16% rated analyst) recently upgraded the stock to Strong Buy with a price target of $11, representing +43.42% upside potential.
• Even the Hold ratings suggest upside, though. RBC Capital's Ben Hendrix (a top 16% rated analyst) maintains a Hold rating but with a $10 price target that still implies +30.38% upside, suggesting potential for rating upgrades ahead. 
• Industry ranking context: AVAH is currently the 3rd highest-rated stock in the Medical Care Facility industry, which has an Industry Rating of A, placing it in an attractive sector.
• Zen Rating highlights: AVAH earns an overall Zen Rating of A, putting it in the top tier of stocks we track based on a rigorous 115-factor review. Stocks in this category have historically delivered market-beating returns. 
• Component Grades: Looking at the Component Grades that shape the overall rating, the stock shines with an A grade in Sentiment reflecting strong analyst optimism post-earnings and a B grade in Value, suggesting a potentially attractive entry point. See all 7 Zen Component Grades here

5- Nature's Sunshine Products (NASDAQ: NATR)

This global wellness powerhouse — manufacturing and selling nutritional and personal care products across Asia, Europe, North America, and Latin America — is firing on all cylinders. Strong Q1 2026 results just drove investor interest sky-high, and with NATR now ranking #1 in the Food industry, this defensive consumer play has Wall Street paying close attention.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $21.93 — get current quote

Max 1-year forecast: $33.00

Why we're watching:

• Analyst support: 2 analysts cover NATR with a unanimous Strong Buy consensus, with price targets that suggest over 50% potential upside. See the ratings
• Canaccord Genuity researcher Susan Anderson (a top 16% rated analyst) recently maintained her Strong Buy rating following the company's Q4 and FY 2025 earnings report. Anderson noted the results showed strength across all regions and strong growth in the company's digital business.
• DA Davidson recently maintained their $33 price target, representing +50.96% upside potential from current levels, highlighting confidence in the company's growth trajectory.
• Despite good earnings and solid backing from analysts, the stock is down for no particular reason — which, as our Editor-in-Chief Steve Reitmeister observed, could make it a fantastic buy the dip opportunity. Read his detailed commentary here.
• Industry ranking context: NATR is currently the #1 highest-rated stock in the Food industry.
• Zen Rating highlights: As a Strong Buy-rated stock, NATR is already in a class of stocks that have historically delivered over 32% annual returns. But within that top tier, it actually ranks in the top 1% of stocks we track based on fundamentals — no small feat. 
• Component Grades: NATR shows exceptional strength with A grades in Value, plus B grades in AI, Financials, and Sentiment, indicating strong analyst conviction and attractive valuation metrics. (See all 7 Zen Component Grades here)

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.